Abstract: The invention relates to the chemically modified genomic sequence of the Cdk4 gene, to oligonucleotides and/or PNA oligomers for detecting the cytosine methylation condition of the Cdk4 gene and to a method for determining genetic and/or epigenetic parameters of the Cdk4 gene.

Abstract: Chemically modified genomic sequences of genes associated with metabolism, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genes associated with metabolism which are directed against the sequence are disclosed. In addition, a method for ascertaining genetic and/or epigenetic parameters of genes associated with metabolism is disclosed.

Abstract: The present invention concerns a method for toxicological diagnosis. A DNA sample is taken from an organism or a cell culture, which has previously been subjected to a specific substance that is to be investigated for its toxicological effect. The DNA contained in this sample is chemically pretreated and the base sequence of a part of the modified DNA is determined. A methylation state characteristic for the sample or a characteristic methylation pattern is concluded from this. The effect of a substance on the organism or the cell culture is concluded by comparison with data of the methylation states of other samples and/or compared with other substances from a toxicological point of view.

Abstract: The invention relates to the chemically modified genomic sequence of the human C-mos gene, to oligonucleotides and/or PNA oligomers directed against the sequence for detecting the cytosine methylation condition of the human C-mos gene and to a method for determining genetic and/or epigenetic parameters of the human C-mos gene.

Abstract: The present invention relates to the chemically modified genomic sequences of genes associated with cell cycle, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genes associated with cell cycle which are directed against the sequence, as well as to a method for ascertaining genetic and/or epigenetic parameters of genes associated with cell cycle.

Abstract: The present invention relates to the chemically modified genomic sequences of genes associated with pharmacogenomics, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genes associated with pharmacogenomics which are directed against the sequence, as well as to a method for ascertaining genetic and/or epigenetic parameters of genes associated with pharmacogenomics.

Abstract: The invention describes a method for the quantitative sequencing of nucleic acids treated with bisulfite. The invention particularly describes a method for the determination of the degree of methylation of a cytosine in the base sequence 5′-CG-3′, thus in a so-called CpG position, if the genomic sequence of the investigated DNA region is known. The invention makes possible the validation of sequence information in the sequencing of DNA treated with bisulfite. It is particularly described how the data obtained with conventional sequencing methods are first standardized with respect to their signal intensity, how the conversion rate of cytosine to uracil after bisulfite treatment is determined from these data, and how a correction factor can be determined with the help of this conversion rate, and this factor produces an essentially improved estimation of the degree of methylation actually present.

Abstract: The present invention describes nucleic acids for the diagnosis of a set of genetic parameters within the major histocompatibility complex (MHC), comprising a segment that is inversely complementary or identical to a chemically pretreated genomic DNA and that is at least 20 base pairs long as well as a set of oligomer probes (oligonucleotides and/or PNA oligomers), which serve for the detection of the cytosine methylation state in nucleic acids. These probes are particularly suitable for the diagnosis of genetic parameters within the MHC.

Abstract: The present invention relates to the chemically modified genomic sequences of genes associated with apoptosis, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genes associated with apoptosis which are directed against the sequence, as well as to a method for ascertaining genetic and/or epigenetic parameters of genes associated with apoptosis.

Abstract: The present invention relates to the chemically modified genomic sequences of genes associated with DNA transcription to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genes associated with DNA transcription which are directed against the sequence as well as to a method for ascertaining genetic and/or epigenetic parameters of genes associated with DNA transcription.

Abstract: The present invention relates to the chemically modified genomic sequences of genes associated with metastasis, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genes associated with metastasis which are directed against the sequence, as well as to a method for ascertaining genetic and/or epigenetic parameters of genes associated with metastasis.

Abstract: The present invention relates to chemically modified genomic sequences of genes associated with the immune system, to oligonucleotides and/or PNA-oligomers directed against the sequence, for the detection of the methylation status of genes, associated with the immune system as well as to a method for ascertaining genetic and/or epigentic parametres of genes, associated with the immune system.

Abstract: The present invention relates to the chemically modified genomic sequences of genes associated with gene regulation, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genes associated with gene regulation which are directed against the sequence, as well as to a method for ascertaining genetic and/or epigenetic parameters of genes associated with gene regulation.

Abstract: This invention concerns systems for collecting and storing epigenetic and phenotypic information about samples in order to measure and analyse tissue samples and/or cell lines, where the epigenetic parameter is DNA methylation and the phenotypic parameters describe an individual. The method includes parameters such as the diagnosis of diseases and/or drug resistance, wherein the correlation of the epigenetic with the phenotypic parameters is done substantially without human intervention.